||
https://mp.weixin.qq.com/s/iHuT0-FGXlA3vI3ulDWwow
选择性免疫蛋白酶体Zetomipzomib具有广泛的免疫调节作用,不仅可有效改善蛋白尿,维持肾脏缓解,减少糖皮质激素的使用,还可改善SLE临床疾病活动性评分,且具有良好的安全性和耐受性。随着未来对Zetomipzomib临床证据的进一步积累,有望为LN患者带来更为精准的个体化治疗方案,进而提升LN患者的治疗效果,改善预后。
http://www.pubmedplus.cn/P/SearchQuickResult?wd=eecf3b3d-b13e-4fae-98f1-e81028e16cc0
Department of Research, Kezar Life Sciences, South San Francisco, CA, United States.
Front Immunol (P 1664-3224 E 1664-3224) H指数:84 2023 年 14 卷 1043680 页
PMID:36969170 相似文献
http://www.pubmedplus.cn/P/SearchQuickResult?wd=625e18ad-bc6c-41b2-81e9-38341ac0e1e3
01. | Lupus Nephritis | 79 篇 | 84.043% |
02. | Animals | 73 篇 | 77.660% |
03. | Humans | 62 篇 | 65.957% |
04. | Mice | 62 篇 | 65.957% |
05. | Lupus Erythematosus, Systemic | 61 篇 | 64.894% |
06. | Female | 50 篇 | 53.191% |
07. | Cytokines | 36 篇 | 38.298% |
08. | Disease Models, Animal | 34 篇 | 36.170% |
09. | Mice, Inbred NZB | 30 篇 | 31.915% |
10. | Leukocytes, Mononuclear | 28 篇 | 29.787% |
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-8-15 14:30
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社